A competitor of antibiotics maker Cubist Pharmaceuticals has agreed not to launch a generic version of its flagship drug for skin infections until at least Dec. 1 while a judge decides on a patent challenge.
In 2012, Illinois-based Hospira indicated it hopes to launch a generic of Cubicin, claiming the patents are invalid. Cubicin remains Cubist’s biggest money-maker, contributing 80 percent of the company’s revenue in the three months that ended in June. The Lexington drug maker has sued Hospira, claiming patent infringement.
Help employers find you! Check out all the jobs and post your resume.
